Sarcoidosis
Conditions
Keywords
sarcoidosis, inspiratory muscle strength, exercise capacity, quality of life
Brief summary
Respiratory muscle weakness results with decreased exercise capacity, worse fatigue, dyspnea and quality of life in patients with sarcoidosis. However, no study investigated the effects of inspiratory muscle training (IMT), therefore effects of IMT on outcomes in patients with sarcoidosis were investigated.
Detailed description
Patients were diagnosed with sarcoidosis according to the criteria of the latest American Thoracic Society (ATS)/European Respiratory Society (ERS)/World Association of Sarcoidosis and Other Granulomatous (WASOG) Disorders statement on sarcoidosis. Primary outcome measurement was respiratory muscle strength, secondary outcomes were, exercise capacity quality of life, fatigue and depression.
Interventions
DEVICEInspiratory muscle training
Treatment group received inspiratory muscle training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 40% of maximal inspiratory pressure (MIP). The MIP was measured at supervised session each week, and 40% of measured MIP value was the new training workload. The treatment group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department.
Control group received sham inspiratory muscle training (IMT) at fixed workload, 5% of MIP using threshold loading device (POWERbreathe Classic device IMT Technologies Ltd. Birmingham, England). The control group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department.
Sponsors
Gazi University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
20 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Clinically stable * Under standard medication * Stage I and IV * No change in medications over three months
Exclusion criteria
* Cognitive disorders * Current corticosteroid use * Having co-morbidity to prevent performing IMT * Acute infection * Orthopedic and neurological problems
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum inspiratory and expiratory muscle strength (MIP, MEP) | 6 weeks | Mouth pressure device |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Maximal Exercise Capacity | 6 weeks | Modified incremental shuttle walk test (ISWT) |
| Fatigue | 6 weeks | Fatigue Severity Scale (FSS) |
| Pulmonary function and diffusing capacity | 6 weeks | Spirometry |
| Exercise Capacity | 6 weeks | Six-minute walk test (6MWT) |
| Dyspnea | 6 weeks | Modified Borg and Modified Medical Research Council (MMRC) dyspnea scales |
| Depression | 6 weeks | Montgomery Asberg Depression Rating Scale (MADRS)) |
| Quality of life | 6 weeks | Saint George's Respiratory Questionnaire (SGRQ) (Turkish versions of all scales) |
| Peripheral muscle strength | 6 weeks | Hand-held dynamometer |
Outcome results
None listed